An Open-label, Multicenter Phase 2 Study Evaluating the Efficacy and Safety of CRG-022, a CD22-Directed Autologous Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Large B-Cell Lymphoma After CD19-Directed CAR T-cell Therapy
ENROLLING
Trial ID:
NCT05972720 Protocol # :
23-365
Phase
II
Disease Sites
Other Hematopoietic
Non-Hodgkin's Lymphoma
Principal Investigator
Jacobson, Caron, A
Site Research Nurses
Babcock, Elise
Bright, Susan
Logan, Emma, Kristen
Maciejewski, Ashley, Taylor
Smith, Caitlin
Tichon, Jennifer
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #23-365
23-365